Araz Marachelian, MD

Assistant Professor of Clinical Pediatrics

Image of Araz Marachelian, MD
Is this your profile? Click to edit

Awards

  • NCI Cancer Clinical Investigator Team Leadership Award (CCITLA), 2014-2015
  • Southern California Super Doctors, 2014
  • Pasadena Magazine: Top Doctor, 2013
  • Southern California Super Doctors, 2009-2010
  • AACR/ASCO: Clinical Trial Training Workshop Award, 2005
  • University of California, Irvine: Outstanding Achievement in Pediatrics and Psychiatry, 1999
  • University of California, Berkeley: High Distinction of Honors, 1995
  • University of California, Berkeley: Outstanding Service Award, 1995
  • Undergraduate Research Award National Science Foundation, 1994

Publications

  • Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial Br J Cancer. 2024 Jan 10. . View in PubMed
  • Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma Pediatr Blood Cancer. 2024 Jan; 71(1):e30743. . View in PubMed
  • Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study Cancer. 2023 Dec 15. . View in PubMed
  • Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus Pediatr Blood Cancer. 2023 05; 70(5):e30217. . View in PubMed
  • Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results Nat Med. 2023 05; 29(5):1092-1102. . View in PubMed
  • Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma Nat Commun. 2023 05 05; 14(1):2601. . View in PubMed
  • Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma Sci Rep. 2023 11 14; 13(1):19915. . View in PubMed
  • Congenital central hypoventilation syndrome without hypoventilation: is it congenital central hypoventilation syndrome? J Clin Sleep Med. 2023 06 01; 19(6):1161-1164.. View in PubMed
  • Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma Int J Radiat Oncol Biol Phys. 2023 04 01; 115(5):1115-1128. . View in PubMed
  • Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy Pediatr Blood Cancer. 2022 09; 69(9):e29719. . View in PubMed
  • Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures Radiat Res. 2022 02 01; 197(2):101-112. . View in PubMed
  • Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium J Clin Oncol. 2021 11 01; 39(31):3506-3514. . View in PubMed
  • Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer J Pain Symptom Manage. 2020 10; 60(4):782-789. . View in PubMed
  • Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature Pediatr Blood Cancer. 2020 08; 67(8):e28236. . View in PubMed
  • The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors J Surg Res. 2020 05; 249:8-12. . View in PubMed
  • Unrealistic parental expectations for cure in poor-prognosis childhood cancer Cancer. 2020 01 15; 126(2):416-424. . View in PubMed
  • Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531 J Clin Oncol. 2019 12 01; 37(34):3243-3255. . View in PubMed
  • Rare MYC-amplified Neuroblastoma With Large Cell Histology Pediatr Dev Pathol. 2018 Sep-Oct; 21(5):461-466. . View in PubMed
  • Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial Pediatr Blood Cancer. 2018 07; 65(7):e27023. . View in PubMed
  • Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v10) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 05; 65(5):e26940. . View in PubMed
  • Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma Clin Cancer Res. 2018 12 15; 24(24):6142-6149. . View in PubMed
  • Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors Bone Marrow Transplant. 2017 Nov; 52(11):1543-1548. . View in PubMed
  • Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. . View in PubMed
  • The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. . View in PubMed
  • Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial J Clin Oncol. 2016 Apr 20; 34(12):1368-75. . View in PubMed
  • Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG) Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. . View in PubMed
  • Comparative pharmacokinetics, safety, and tolerability of two sources of ch1418 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. . View in PubMed
  • Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine Eur J Cancer. 2016 10; 66:144-52. . View in PubMed
  • A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma Pediatr Blood Cancer. 2016 08; 63(8):1349-56. . View in PubMed
  • The clinical management and outcomes of cervical neuroblastic tumors J Surg Res. 2016 07; 204(1):109-13. . View in PubMed
  • Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. . View in PubMed
  • 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastomaA new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. . View in PubMed
  • Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. . View in PubMed
  • Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study BMC Res Notes. 2014 Apr 23; 7:256. . View in PubMed
  • Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. . View in PubMed
  • Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. . View in PubMed
  • Forearm skeletal muscle neuroblastoma in a child: a rare primary location J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. . View in PubMed
  • The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma Pediatr Blood Cancer. 2012 May; 58(5):675-81. . View in PubMed
  • Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial Clin Cancer Res. 2012 May 01; 18(9):2679-86. . View in PubMed
  • A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. . View in PubMed
  • Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. . View in PubMed
  • Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. . View in PubMed
  • High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome Cancer. 2009 Jul 01; 115(13):2956-63. . View in PubMed
  • Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors Bone Marrow Transplant. 2008 Jan; 41(2):167-72. . View in PubMed
  • Predictors of outcome in children with Langerhans cell histiocytosis Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. . View in PubMed